Table 1. Baseline characteristics of genotype I chronic hepatitis C patients treated with PegIFN/RBV and sustained virological response.
| Variable | Total(N = 191) | Non-SVR(N = 60) | SVR(N = 131) | P value |
| Sex, n (%) | 0.131 | |||
| male | 123 (64.4) | 26 (43.3) | 42 (32.1) | |
| female | 68 (35.6) | 34 (56.7) | 89 (67.9) | |
| Baseline Viral Load (mean ± SD) | <0.001 | |||
| <0.4×106 IU/ml | 91 (47.6) | 16 (26.7) | 75 (57.3) | |
| ≥0.4×106 IU/ml | 100 (52.4) | 44 (73.3) | 56 (42.7) | |
| Fibrosis Stage, n (%) | 0.021 | |||
| F0-2 | 103 (53.9) | 25 (41.7) | 78 (59.5) | |
| F3-4 | 88 (46.1) | 35 (58.3) | 53 (40.5) | |
| Age, y (mean ± SD) | 51.4±11.1 | 53.6±10.3 | 50.3±11.4 | 0.063 |
| BMI, Kg/m2 (mean ± SD) | 24.5±3.3 | 25.2±3.1 | 24.2±3.4 | 0.049 |
| HbA1c, % (mean ± SD) | 5.6±1.0 | 5.7±1.1 | 5.6±1.0 | 0.443 |
| ALB, g/dL (mean ± SD) | 4.5±0.4 | 4.4±0.4 | 4.5±0.3 | 0.507 |
| AST, IU/L (mean ± SD) | 92.0±51.6 | 89.6±2.0 | 93.1±51.5 | 0.532 |
| ALT, IU/L (mean ± SD) | 149.1±107.2 | 129.4±1.2 | 158.2±116.3 | 0.068 |
| GGT, IU/L (mean ± SD) | 42.9±48.5 | 51.9±60.0 | 38.8±41.9 | 0.034 |
| ALP, IU/L (mean ± SD) | 79.5±25.2 | 81.9±27.6 | 78.3±24.0 | 0.443 |
| Bilirubin, mg/dL (mean ± SD) | 0.9±0.3 | 1.0±0.3 | 0.9±0.3 | 0.213 |
| RVR, n (%) | 133 (69.6) | 28 (46.7) | 105 (80.2) | <0.001 |
| EVR, n (%) | 183 (95.8) | 54 (90.0) | 129 (98.5) | 0.007 |
BMI: body mass index. ALB: albumin; AST: aspartate transaminase; ALT: alanine transaminase; GGT: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase; SVR: sustained viralogical response; RVR: rapid virological response; EVR: early virological response.